See more : Stanmore Resources Limited (STMRF) Income Statement Analysis – Financial Results
Complete financial analysis of Eden Research plc (EDNSF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eden Research plc, a leading company in the Agricultural Inputs industry within the Basic Materials sector.
You may be interested
- Choei Inc. (2993.T) Income Statement Analysis – Financial Results
- Disruptive Capital Acquisition Company Limited (DCACS.AS) Income Statement Analysis – Financial Results
- Marshall Machines Limited (MARSHALL.NS) Income Statement Analysis – Financial Results
- Hestia Insight Inc. (HSTA) Income Statement Analysis – Financial Results
- Indo Count Industries Limited (ICIL.BO) Income Statement Analysis – Financial Results
Eden Research plc (EDNSF)
About Eden Research plc
Eden Research plc offers sustainable solutions for crop protection, animal health, and consumer products in the United Kingdom and rest of Europe. The company provides crop protection products for foliar disease and insect control, open field and greenhouses, soil pests, post-harvest shelf-life extension, and seed treatment applications. It also offers animal health products, such as companion animal, bio-control, parasite treatments, and insect spray products. In addition, the company provides human health products comprising head-lice treatment products, fragrances, deodorants, wound-care products, food flavorings, odor neutralizers, and active ingredient supply/delivery products. The company was incorporated in 1995 and is headquartered in Abingdon, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.19M | 1.83M | 1.23M | 1.37M | 2.05M | 2.77M | 1.88M | 391.96K | 883.31K | 99.86K | 80.22K | 43.59K | 91.00K | 172.00K | 193.00K |
| Cost of Revenue | 1.43M | 997.01K | 667.34K | 736.51K | 1.16M | 1.24M | 831.50K | 28.56K | 98.71K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.77M | 830.16K | 561.24K | 632.48K | 883.86K | 1.54M | 1.05M | 363.40K | 784.60K | 99.86K | 80.22K | 43.59K | 91.00K | 172.00K | 193.00K |
| Gross Profit Ratio | 55.31% | 45.43% | 45.68% | 46.20% | 43.16% | 55.41% | 55.71% | 92.71% | 88.83% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 291.44K | 284.17K | 214.68K | 315.19K | 231.08K | 183.02K | 290.28K | 225.14K | 200.09K | 179.82K | 154.51K | 0.00 | 0.00 | 25.00K | 35.00K |
| General & Administrative | 3.00M | 2.75M | 2.69M | 2.20M | 1.54M | 1.52M | 1.62M | 1.44M | 1.02M | 1.02M | 1.03M | 890.38K | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.00M | 2.75M | 2.69M | 2.20M | 1.54M | 1.52M | 1.62M | 1.44M | 1.02M | 1.02M | 1.03M | 890.38K | 0.00 | 0.00 | 0.00 |
| Other Expenses | 343.10K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 3.63M | 3.40M | 3.77M | 2.87M | 2.24M | 2.03M | 2.40M | 2.25M | 1.92M | 1.85M | 1.67M | 1.70M | 1.92M | 2.43M | 1.83M |
| Cost & Expenses | 5.06M | 4.39M | 4.44M | 3.60M | 3.41M | 3.27M | 3.23M | 2.28M | 2.02M | 1.85M | 1.67M | 1.70M | 1.92M | 2.43M | 1.83M |
| Interest Income | 34.01K | 192.00 | 98.00 | 5.73K | 807.00 | 1.68K | 2.53K | 1.28K | 247.00 | 117.00 | 316.00 | 393.00 | -202.39K | -71.00K | 0.00 |
| Interest Expense | 17.01K | 22.05K | 32.07K | 24.00K | 8.40K | 1.68K | 1.24K | 1.28K | 247.00 | 1.25M | 24.00 | 12.32K | 1.26M | 945.00K | 157.00K |
| Depreciation & Amortization | 625.08K | 687.44K | 589.97K | 622.85K | 518.81K | 429.87K | 750.21K | 680.39K | 655.30K | 635.04K | 630.27K | 719.13K | 697.00K | 664.00K | 656.00K |
| EBITDA | -6.28M | -1.86M | -2.77M | -1.99M | -952.17K | -102.65K | -601.09K | -1.21M | -483.33K | -1.11M | -1.11M | -1.60M | -1.34M | -1.67M | -980.00K |
| EBITDA Ratio | -196.68% | -101.69% | -225.76% | -117.00% | -46.49% | -2.42% | -62.41% | -307.68% | -54.72% | -2,366.21% | -1,243.91% | -3,675.67% | -1,469.23% | -972.67% | -509.84% |
| Operating Income | -1.87M | -2.57M | -3.21M | -2.24M | -1.36M | -497.04K | -780.84K | -1.89M | -1.14M | -1.75M | -1.58M | -1.66M | -1.83M | -2.26M | -1.64M |
| Operating Income Ratio | -58.48% | -140.49% | -261.14% | -163.31% | -66.29% | -17.92% | -41.60% | -481.27% | -128.90% | -1,748.17% | -1,975.65% | -3,803.01% | -2,012.09% | -1,315.70% | -847.67% |
| Total Other Income/Expenses | -5.05M | -562.00 | -187.40K | -304.84K | -121.76K | -36.03K | 17.91K | -26.62K | -119.73K | -1.25M | -43.27K | -619.53K | -1.46M | -1.02M | -157.00K |
| Income Before Tax | -6.92M | -2.57M | -3.40M | -2.55M | -1.48M | -533.07K | -762.93K | -1.91M | -1.16M | -3.00M | -1.63M | -2.33M | -3.29M | -3.28M | -1.79M |
| Income Before Tax Ratio | -216.80% | -140.52% | -276.39% | -186.13% | -72.23% | -19.21% | -40.64% | -488.06% | -131.20% | -3,002.17% | -2,029.59% | -5,353.70% | -3,614.29% | -1,908.14% | -929.02% |
| Income Tax Expense | -428.33K | -323.72K | -618.14K | -285.11K | -347.04K | -198.12K | -123.84K | -81.90K | -101.26K | -28.35K | -40.29K | -16.54K | -5.00K | -31.00K | -66.00K |
| Net Income | -6.49M | -2.24M | -2.79M | -2.27M | -1.14M | -334.95K | -639.09K | -1.83M | -1.06M | -2.97M | -1.59M | -2.32M | -3.28M | -3.25M | -1.73M |
| Net Income Ratio | -203.45% | -122.44% | -227.01% | -165.84% | -55.89% | -12.07% | -34.05% | -467.17% | -119.73% | -2,973.78% | -1,979.37% | -5,315.75% | -3,608.79% | -1,890.12% | -894.82% |
| EPS | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | -0.01 | -0.01 | -0.02 | -0.01 | -0.02 | -0.03 | -0.03 | -0.02 |
| EPS Diluted | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | -0.01 | -0.01 | -0.02 | -0.01 | -0.02 | -0.03 | -0.03 | -0.02 |
| Weighted Avg Shares Out | 420.92M | 380.55M | 380.34M | 344.63M | 208.57M | 207.43M | 196.01M | 178.72M | 155.93M | 125.76M | 121.98M | 107.48M | 111.22M | 111.22M | 111.22M |
| Weighted Avg Shares Out (Dil) | 420.92M | 380.55M | 380.34M | 344.63M | 208.57M | 207.43M | 196.01M | 178.72M | 155.93M | 125.95M | 122.16M | 107.48M | 111.22M | 111.22M | 111.22M |
Eden Research CEO talks revenue growth and regulatory wins - ICYMI
Eden Research PLC (AIM:EDEN, OTCQB:EDNSF) CEO Sean Smith talked with Proactive about recent developments, including the company's growth and new regulatory achievements. Smith highlighted the second consecutive approval for Ecovelex in Italy, an important product in their bio-pesticide lineup.
Eden Research hails another year of 'sizeable growth'
Eden Research PLC (AIM:EDEN, OTCQB:EDNSF) CEO Sean Smith is forecasting another period of “sizeable growth” as the benefits of the investment made over the last years start to translate into strong sales growth. Revenues for 2024 are expected to rise by 34% to...
Eden Research eyes more growth with label extensions and approvals - ICYMI
Eden Research PLC (AIM:EDEN, OTCQB:EDNSF) CEO Sean Smith talked with Proactive about the company's strong performance in the first half of the year, including a 65% jump in revenue to £1.89 million. Smith highlighted the key role of regulatory approvals...
Eden Research revenue surges as regulatory momentum continues
Eden Research PLC (AIM:EDEN, OTCQB:EDNSF) reported 65% growth in revenue for the first half of 2024 and said it is on track to hit full-year targets. The biopesticides maker generated revenue of £1.89 million in the six months to end-June,...
Eden Research: Greek authorities grant temporary approval for key product
Sustainable biopesticides specialist Eden Research PLC (AIM:EDEN, OTCQB:EDNSF) (AIM: EDEN) said its product Cedroz has received temporary approval for use in Greece during the 2024 growing season. The go-ahead, granted under Regulation EU/1107/2009, allows Cedroz to be applied to potatoes to...
Eden Research moving rapidly in Germany after approval says CEO - ICYMI
Eden Research PLC (AIM:EDEN, OTCQB:EDNSF) CEO Sean Smith discusses with Proactive the regulatory approval for fungicide Mevalone in Germany, its fourth approval in a year. Sean Smith: It's very good news and very good progress.
Eden Research appoints new head of regulatory affairs
Eden Research PLC (AIM:EDEN, OTCQB:EDNSF) has appointed Ilshad Moulan as the company's new head of regulatory affairs. With a strong background in the agrochemical sector, Moulan will lead Eden's regulatory strategy and execution, focusing on the global registration of its...
Source: https://incomestatements.info
Category: Stock Reports